Publications by authors named "Paul Schellhammer"

Claim this Profile
C
Comment on: 'Preferences between three options for androgen deprivation therapy…'.
Richard Wassersug, Robert Watson, Carly Sears, Paul Schellhammer

BJU Int· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tribute to Michael Droller MD.
Paul H Lange, Paul F Schellhammer

Urol Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Christoper J. Logothetis, Andrew W. Hahn. Challenging the Prevailing Therapeutic Dogma for Prostate Cancer: The Case for an Overlap Syndrome. Eur Urol 2024;85:3-7.
Richard J Wassersug, Paul F Schellhammer, Erik Wibowo

Eur Urol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A history of the Society of Urologic Oncology.
Paul H Lange, Michael S Cookson, Paul F Schellhammer, Michael J Droller

Urol Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer.
Neal D Shore, Paul F Schellhammer, Ronald F Tutrone, Neil F Mariados, Stacey S Harrelson

Clin Genitourin Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry.
Oliver Sartor, Andrew J Armstrong, Chiledum Ahaghotu, David G McLeod, Matthew R Cooperberg, Paul F Schellhammer

Prostate Cancer Prostatic Dis· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
E David Crawford, Paul F Schellhammer, David G McLeod, Judd W Moul, Celestia S Higano

J Urol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oestrogen redux: will transdermal delivery rebalance the risk-benefit equation?
Paul F Schellhammer

BJU Int· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Urologist's Personal View of Prostate Cancer.
Paul F Schellhammer

Turk J Urol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Legends in Urology.
Paul F Schellhammer

Can J Urol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Should the Urologist Treat Castration Resistant Prostate Cancer? Yes/No.
Paul F Schellhammer

J Urol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical and economic implications of specimen provenance complications in diagnostic prostate biopsies.
Kirk Wojno, John Hornberger, Paul Schellhammer, Minghan Dai, Travis Morgan

J Urol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic castrate-resistant prostate cancer.
Paul Schellhammer

Urol Oncol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Stephen H Culp, Paul F Schellhammer, Michael B Williams

Eur Urol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gonadal steroids and body composition, strength, and sexual function in men.
Paul F Schellhammer

N Engl J Med· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life after sipuleucel-T therapy: results from a randomized, double-blind study in patients with androgen-dependent prostate cancer.
Tomasz M Beer, Paul F Schellhammer, John M Corman, L Michael Glodé, Simon J Hall

Urology· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing.
Marc A Bjurlin, H Ballentine Carter, Paul Schellhammer, Michael S Cookson, Leonard G Gomella

J Urol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial.
Paul F Schellhammer, Gerald Chodak, James B Whitmore, Robert Sims, Mark W Frohlich

Urology· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermittent versus continuous androgen deprivation in prostate cancer.
Maha Hussain, Catherine M Tangen, Donna L Berry, Celestia S Higano, E David Crawford, Paul F Schellhammer

N Engl J Med· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treater to target: a urologist's personal experience with prostate cancer.
Paul F Schellhammer

J Natl Cancer Inst Monogr· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Life after failure of traditional androgen deprivation therapy.
Paul Schellhammer

Urol Oncol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intermittent androgen suppression for rising PSA level after radiotherapy.
Juanita M Crook, Christopher J O'Callaghan, Graeme Duncan, David P Dearnaley, Celestia S Higano, Paul F Schellhammer

N Engl J Med· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
Philip W Kantoff, Celestia S Higano, Eric J Small, James B Whitmore, Mark W Frohlich, Paul F Schellhammer

J Natl Cancer Inst· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re: Prediction of erectile function following treatment for prostate cancer.
Paul Schellhammer

Eur Urol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment options for localized prostate cancer.
Ravinder Mohan, Paul F Schellhammer

Am Fam Physician· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis